NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan Mangini, President and Chief Financial Officer, will participate in the B. Riley Securities 3rd Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 19th, at 11:00 am ET.
Related news for (NGM)
- Federman & Sherwood Announces Investigation Into NeoGames, SA (NASDAQ: NGMS) And Encourages Investors to Contact the Firm
- NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
- NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®